June 2025 – Clinical Trial Results

Dr. Daniel Judge and Dr. C. Michael Gibson discuss data presented at ACC 2025: Primary Endpoint Efficacy Results in The Attribute-CM Study: Pre-Specified Sensitivity Analyses Addressed Tafamidis Use. Sponsored by BridgeBio Pharma, Inc

June 16, 2025

Disclosures: Sponsored by BridgeBio Pharma, Inc.

Dr. Nitasha Sarswat and Dr. C. Michael Gibson discuss datapresented at ACC 2025: Acoramidis-Mediated Early Increase in Serum Transthyretin Level Reduces Cardiovascular-Related Hospitalizations and Mortality: Insights From The Attribute-CM Study

June 13, 2025

Disclosures: Sponsored by BridgeBio Pharma, Inc

Dr. Brett Sperry and Dr. C. Michael Gibson discuss: Atrial fibrillation, arrythmias, and other cardiac manifestations in patients with ATTR-CM

June 11, 2025

Disclosures: Sponsored by BridgeBio Pharma, Inc.

Dr. Ron Witteles and Dr. C. Michael Gibson discuss: Atrial fibrillation, arrythmias, and other cardiac manifestations in patients with ATTR-CM

June 9, 2025

Disclosures: Sponsored by BridgeBio Pharma, Inc.

Dr. Richard Cheng and Dr. C. Michael Gibson discuss: Presentation, screening, and disease progression of variant ATTR-CM

June 4, 2025

Disclosures: Sponsored by BridgeBio Pharma, Inc

Dr. Kevin Alexander and Dr. C. Michael Gibson discuss datapresented at ACC 2025: Dr. Kevin Alexander, Acoramidis Improves Serum TTR Levels in Patients with Wild-Type or Variant Transthyretin Amyloid Cardiomyopathy sponsored byBridgeBio Pharma, Inc.

June 2, 2025

Disclosures: Sponsored by BridgeBio Pharma, Inc.